$PODD · INSULET CORP
Insulet reported Q3 FY2026 results: revenue of $842.0M, up 19.2% (19.6% constant currency), slightly above the high end of guidance. Net income was $141.1M ($2.03 diluted EPS) vs $87.6M ($1.24) a year ago; adjusted EPS was $1.99, up 59.9%. The board authorized a $1B share repurchase program through Dec 31, 2028, with ~$400M planned for Q4 2026 funded by existing cash.
- Revenue $842.0M, +19.2% YoY (19.6% constant currency), above high end of guidance.
- Net income $141.1M ($2.03 diluted EPS) vs $87.6M ($1.24) prior year.
- Adjusted EPS $1.99, up 59.9% YoY.
- Operating margin 22.5%, up 590bps YoY.
- $1B buyback authorized; ~$400M planned for Q4 2026.
Extended-hours last trade $162.06, +4.65% vs regular close of $154.86, signaling a positive reaction to the beat and buyback.
A beat-and-raise quarter paired with a $1B buyback signals strong execution and capital-return confidence.
Strong international growth (+31.7% Omnipod) and margin expansion reinforce Insulet's position in the diabetes device space against peers.
Dependence on a principal product platform (Omnipod), tariff expansion, and competitive/technological pressures are cited as key risks.